Navigation Links
Roche to Acquire Ventana for $89.50 per share
Date:1/22/2008

Roche and Ventana Reach Definitive Merger Agreement

BASEL, Switzerland and TUCSON, Ariz., Jan. 22 /PRNewswire-FirstCall/ -- Roche (SWX: ROG.VX; RO.S; OTCQX: RHHBY), a world-leading healthcare provider of pharmaceuticals and diagnostics, and Ventana Medical Systems ("Ventana") (Nasdaq: VMSI) today announced that they have signed a definitive merger agreement. Under the terms of the agreement, Roche will increase the purchase price in the tender offer for Ventana common shares to $89.50 per share in cash (or an aggregate of approximately $3.4 billion on a fully diluted basis), and Ventana's Board of Directors will recommend that Ventana's shareholders tender their shares to Roche. The merger agreement has been approved by the boards of Ventana and Roche. This offer represents a premium of 4.9% to Ventana's closing price on January 18, 2008, a 19.3% premium to Roche's initial offer on June 27, 2007, and a 72.3% premium to Ventana's closing price on June 22, 2007 (the last trading day prior to the announcement of Roche's initial offer). The acquisition of Ventana, a leader in the fast-growing histopathology (tissue-based diagnostics) segment, will allow Roche to broaden its diagnostic offerings and complement its world leadership in both in-vitro diagnostic systems and oncology therapies.

Under the terms of the merger agreement, Roche will amend its existing tender offer to acquire all of the outstanding common shares of Ventana to reflect the terms of the merger agreement. The amended offer will increase the offer price to $89.50 per share in cash, expire at 7:00 p.m., New York City time on Thursday, February 7, 2008 and be subject to, among other things, the conditions that there are validly tendered and not withdrawn,
'/>"/>

SOURCE Roche; Ventana Medical Systems
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Roche Extends Tender Offer for Ventana
2. Amic Signs Non-Exclusive License Agreement With Roche Diagnostics for Key Cardiac Marker NT-proBNP
3. Roche Files IND for Second Genmab Antibody
4. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
5. Roche to Nominate Independent Directors for Election at Ventanas 2008 Annual Stockholders Meeting
6. MacroChem to Present at Equities Magazine Conference December 7, 2007 in New York
7. Roche Diagnostics Launches CoaguChek XS Plus System to Provide New PT/INR Point-of-Care Solution for Non-Waived Anticoagulation Services
8. Kosan to Reacquire Epothilone Program From Roche
9. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
10. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board
11. MacroChem To Participate in PIPEs Conference October 18th and 19th in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Ohio (PRWEB) July 10, 2014 Understanding ... ion channel-expressing cell lines, and the gap that currently ... cells that expand its industry-leading portfolio of validated ion ... on ion channel-expressing cell lines, as ion channels control ... to control this activity creates the potential to treat ...
(Date:7/10/2014)... OMICS Group’s 5th International conference and ... 2014 at Double Tree by Hilton Beijing, China is ... Analytical & Bioanalytical research methods only to facilitate improved ... occasion, Dr. Srinubabu Gedela, MD of OMICS Group Inc ... remarkable one in bringing a unique and international mix ...
(Date:7/10/2014)... PETERSBURG, Russia , July 10, 2014 ... Russian Federation Dmitry Medvedev , presented ... biopharmaceutical company BIOCAD . The Company is developing ... scope of MabNext project BIOCAD develops a number of ... cancer and autoimmune diseases. The ceremony took place at ...
(Date:7/10/2014)... Calif., July 10, 2014   Ceres, Inc . ... seed company, announced today financial results for the three ... on its business. Ceres reported that the ... product performance this growing season in Brazil, which concluded ... the company,s sorghum evaluation areas for part of the ...
Breaking Biology Technology:Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9
... Raise $7.5 Million in Non-Dilutive Financing from, ... - Vasogen Inc. (NASDAQ: VSGN ; TSX:VAS) and IntelliPharmaCeutics ... agreement, subject to shareholder and regulatory approvals, whereby Vasogen will ... to continue as a publicly-traded entity to be called IntelliPharmaCeutics ...
... SHANGHAI, Aug. 17 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc.,(Nasdaq: ... the manufacture, research, development, marketing and,distribution of probiotics products, today ... fiscal year, ended June 30, 2009. , , ... sales increased 35.5% year-over-year to $15.4 million, ...
... is the first of its kind to emit visible ... technologies based on "nanophotonic" circuitry, said Vladimir Shalaev, the ... Engineering at Purdue University. Such circuits will require ... small enough to integrate them into electronic chips. Now ...
Cached Biology Technology:Vasogen and IntelliPharmaCeutics to Combine to Create Publicly-traded Specialty Pharmaceutical Company 2Vasogen and IntelliPharmaCeutics to Combine to Create Publicly-traded Specialty Pharmaceutical Company 3Vasogen and IntelliPharmaCeutics to Combine to Create Publicly-traded Specialty Pharmaceutical Company 4Vasogen and IntelliPharmaCeutics to Combine to Create Publicly-traded Specialty Pharmaceutical Company 5Vasogen and IntelliPharmaCeutics to Combine to Create Publicly-traded Specialty Pharmaceutical Company 6Vasogen and IntelliPharmaCeutics to Combine to Create Publicly-traded Specialty Pharmaceutical Company 7Vasogen and IntelliPharmaCeutics to Combine to Create Publicly-traded Specialty Pharmaceutical Company 8Vasogen and IntelliPharmaCeutics to Combine to Create Publicly-traded Specialty Pharmaceutical Company 9China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 2China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 3China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 4China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 5China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 6China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 7China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 8China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 9China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 10China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 11New nanolaser key to future optical computers and technologies 2New nanolaser key to future optical computers and technologies 3
(Date:7/11/2014)... Researchers have pioneered a revolutionary new way ... called Virtual Finger, allows scientists to move through ... synapses using the flat surface of their computer ... studies orders of magnitude more efficient, saving time, ... many areas of experimental biology. The software and ...
(Date:7/11/2014)... exists that cannabinoid receptor type 1 can ... influx, and reduce neurotransmitter release. However, some ... can increase extracellular Ca2+ influx and increase ... team, Tongji Hospital Affiliated to Tongji Medical ... China used whole cell voltage-clamp and calcium ...
(Date:7/10/2014)... Colo. , June 27, 2014  The ... the National Institute of Standards and Technology (NIST) ... of its academic research and forensic science expert ... The Board is an element of the NIST,s ... members are among the first appointments made to ...
Breaking Biology News(10 mins):Virtual finger enables scientists to navigate and analyze complex 3D images 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 3
... research published today in BioMed Central,s open access journal ... Rafflesia cantleyi , with its 50cm diameter flowers, has ,stolen, ... these genes shows that their functions range from respiration to ... parasites own gene activity. Vertical gene transfer is that ...
... of North America, are in trouble mostly because of inadequate ... impact, according to work published June 6 in the open ... led by Katherine Ayres, who completed the work while at ... fecal thyroid and glucocorticoid, to distinguish between two different theories ...
... Communities of microbial organisms -- species such as ... Gulf of Mexico changed significantly following the Deepwater Horizon ... of New Hampshire,s Hubbard Center for Genome Studies (HCGS) ... from five Gulf Coast sites prior to and several ...
Cached Biology News:Parasitic plants 'steal' genes from their hosts 2Microbial communities shifted dramatically after Deepwater Horizon spill 2
...
...
... cabinets Heraeus HERAsafe KS convince with an optimum ... new frameless slanted window does not obscure the ... window design makes it easy to work in ... a height of more than 250 mm ensures ...
... Thermo has recently launched a custom ... RNA (siRNA). Thermos siRNA molecules are: ... with 2 DNA bases overhang at ... Delivered fully deprotected and ready-to-use. ...
Biology Products: